PortfoliosLab logoPortfoliosLab logo
CURE.DE vs. WELP.DE
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CURE.DE vs. WELP.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (WELP.DE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CURE.DE achieves a 0.01% return, which is significantly lower than WELP.DE's 25.35% return.


CURE.DE

1D
0.00%
1M
11.67%
YTD
0.01%
6M
-0.48%
1Y
14.68%
3Y*
-0.09%
5Y*
10Y*

WELP.DE

1D
0.00%
1M
-7.19%
YTD
25.35%
6M
26.72%
1Y
34.31%
3Y*
12.49%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CURE.DE vs. WELP.DE - Yearly Performance Comparison


2026 (YTD)2025202420232022
CURE.DE
VanEck Genomics and Healthcare Innovators UCITS ETF A
0.01%5.09%0.30%-6.42%-4.11%
WELP.DE
HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF
25.35%-1.54%7.90%0.25%5.34%

Correlation

The correlation between CURE.DE and WELP.DE is -0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.06

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (All Time)
Calculated using the full available price history since Sep 20, 2022

0.14

The correlation between CURE.DE and WELP.DE shifts across timeframes, from -0.06 (1 year) to 0.14 (all time), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CURE.DE vs. WELP.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CURE.DE
CURE.DE Risk / Return Rank: 2020
Overall Rank
CURE.DE Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
CURE.DE Sortino Ratio Rank: 2222
Sortino Ratio Rank
CURE.DE Omega Ratio Rank: 2020
Omega Ratio Rank
CURE.DE Calmar Ratio Rank: 1919
Calmar Ratio Rank
CURE.DE Martin Ratio Rank: 1717
Martin Ratio Rank

WELP.DE
WELP.DE Risk / Return Rank: 5757
Overall Rank
WELP.DE Sharpe Ratio Rank: 5959
Sharpe Ratio Rank
WELP.DE Sortino Ratio Rank: 5252
Sortino Ratio Rank
WELP.DE Omega Ratio Rank: 5555
Omega Ratio Rank
WELP.DE Calmar Ratio Rank: 6464
Calmar Ratio Rank
WELP.DE Martin Ratio Rank: 5555
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CURE.DE vs. WELP.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (WELP.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CURE.DEWELP.DEDifference
Sharpe ratioReturn per unit of total volatility

-1.03

Sortino ratioReturn per unit of downside risk

-1.09

Omega ratioGain probability vs. loss probability

1.13

1.31

-0.17

Calmar ratioReturn relative to maximum drawdown

0.77

2.80

-2.02

Martin ratioReturn relative to average drawdown

1.66

8.57

-6.91

CURE.DE vs. WELP.DE - Sharpe Ratio Comparison

The current CURE.DE Sharpe Ratio is 0.72, which is lower than the WELP.DE Sharpe Ratio of 1.75. The chart below compares the historical Sharpe Ratios of CURE.DE and WELP.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CURE.DE vs. WELP.DE - Drawdown Comparison

The maximum CURE.DE drawdown since its inception was -34.80%, which is greater than WELP.DE's maximum drawdown of -23.55%. Use the drawdown chart below to compare losses from any high point for CURE.DE and WELP.DE.


Loading charts...

Drawdown Indicators


CURE.DEWELP.DEDifference

Max Drawdown

Largest peak-to-trough decline

-34.80%

-23.55%

-11.25%

Max Drawdown (1Y)

Largest decline over 1 year

-19.07%

-12.22%

-6.85%

Max Drawdown (3Y)

Largest decline over 3 years

-29.29%

-23.55%

-5.74%

Current Drawdown

Current decline from peak

-11.12%

-11.07%

-0.05%

Average Drawdown

Average peak-to-trough decline

-15.12%

-7.79%

-7.33%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.87%

3.99%

+4.88%

Volatility

CURE.DE vs. WELP.DE - Volatility Comparison

VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) has a higher volatility of 7.10% compared to HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (WELP.DE) at 6.59%. This indicates that CURE.DE's price experiences larger fluctuations and is considered to be riskier than WELP.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CURE.DEWELP.DEDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.10%

6.59%

+0.51%

Volatility (6M)

Calculated over the trailing 6-month period

15.59%

16.90%

-1.31%

Volatility (1Y)

Calculated over the trailing 1-year period

20.41%

19.54%

+0.87%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

20.75%

20.07%

+0.68%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

20.75%

20.07%

+0.68%

CURE.DE vs. WELP.DE - Expense Ratio Comparison

CURE.DE has a 0.35% expense ratio, which is lower than WELP.DE's 0.59% expense ratio.


Dividends

CURE.DE vs. WELP.DE - Dividend Comparison

CURE.DE has not paid dividends to shareholders, while WELP.DE's dividend yield for the trailing twelve months is around 3.05%.


Frequently Asked Questions


CURE.DE and WELP.DE have a correlation of -0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, CURE.DE is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

CURE.DE is cheaper with a 0.35% expense ratio, compared with 0.59% for WELP.DE.

CURE.DE tracks MVIS Global Future Healthcare ESG, while WELP.DE tracks MSCI World/Energy NR USD. They also come from different issuers: VanEck and Amundi. Their fees differ too: 0.35% for CURE.DE and 0.59% for WELP.DE.

Portfolio Optimizer

Find the right allocation for CURE.DE and WELP.DE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer